Literature DB >> 12798476

Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses.

Maria A Zoppi1, Rosa M Ibba, Marcella Floris, Fabiola Manca, Carolina Axiana, Giovanni Monni.   

Abstract

OBJECTIVE: To investigate the dynamic trend of the nuchal translucency thickness between fetuses with normal and abnormal karyotype.
DESIGN: Prospective observational study.
SETTING: Ospedale Microcitemico, Cagliari, Italy. POPULATION: A cohort of 305 first trimester fetuses.
METHODS: Fetuses with a nuchal translucency greater than or equal to the 95th centile were invited for a second nuchal translucency measurement. The finding of an 'increased or unchanged' or 'diminished' thickness was compared in fetuses with normal and abnormal karyotype. MAIN OUTCOME MEASURES: Nuchal translucency and karyotype. Median maternal age was 35 years (min 17, max 44) and median crown-rump length at first visit was 50 mm (min 38, max 80). A second nuchal translucency measurement was carried out in 292 fetuses, resulting in increased or unchanged values in 95 cases and decreased nuchal translucency in 197 cases. Two hundred and twenty-six (77.4%) fetuses had normal karyotype and 66 (22.6%) had abnormal karyotype (44 trisomies 21, 10 trisomies 18, 5 trisomies 13, 4 cases of 45 X0, 1 case of 47,XXY, 1 case of 47,XXX and 1 translocation). In the 66 chromosomally abnormal fetuses, the second nuchal translucency measurement was enlarged or unchanged in 37 (56%), and diminished in 29 (44%), while in the 226 normal fetuses the second nuchal translucency measurement was enlarged or unchanged in 58 cases (25%) and diminished in 168 (75%) (relative risk 2.6, 95% confidence interval 1.7-4.0).
CONCLUSION: In fetuses with abnormal karyotype, the second nuchal translucency measurement tends to be increased or unchanged, while in normal cases the size of nuchal translucency is generally reduced.

Mesh:

Year:  2003        PMID: 12798476

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 2.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Increased nuchal translucency before 11 weeks of gestation: Reason for referral?

Authors:  Malou A Lugthart; Bo B Bet; Fleur Elsman; Karline van de Kamp; Bernadette S de Bakker; Ingeborg H Linskens; Merel C van Maarle; Elisabeth van Leeuwen; Eva Pajkrt
Journal:  Prenat Diagn       Date:  2021-10-08       Impact factor: 3.242

Review 5.  Automated Techniques for the Interpretation of Fetal Abnormalities: A Review.

Authors:  Vidhi Rawat; Alok Jain; Vibhakar Shrimali
Journal:  Appl Bionics Biomech       Date:  2018-06-10       Impact factor: 1.781

Review 6.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 7.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.